MMR
Test Description
Mismatch repair (MMR) proteins (MLH1, PMS2, MSH2 and MSH6) immunohistochemistry is a collective qualitative assay to identify patients eligible for treatment with JEMPERLI® (dostarlimab-gxly) or KEYTRUDA® (pembrolizumab) in MMR deficient (dMMR) solid tumours including endometrial carcinoma, and a combination of KEYTRUDA (pembrolizumab) and LENVIMA (lenvatinib) in MMR proficient (pMMR) endometrial carcinoma.
Therapy and associated indication:
Ordering Information
Test Code: MMR
System: VENTANA
Genes: MLH1, PMS2, MSH2, MSH6
Turnaround Time: 3 – 5 working days, upon sample receipt
Accepted Specimens:
- FFPE Tissue/Cell Blocks
- FFPE Slides
Refer to Specimen Requirements for more information.